menu Search
Corpulax

Corpulax

amlodipine

Manufacturer:

Mars Therapeutics

Distributor:

Corbridge
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Amlodipine
Indications/Uses
HTN & CAD eg, chronic stable angina & angiographically documented CAD in patients w/ heart failure or ejection fraction <40%.
Click to view Corpulax detailed prescribing information
Dosage/Direction for Use
HTN, stable angina, Prinzmetal's angina Initially 5 mg once daily, increased to 10 mg once daily, if necessary. Ped Initially 2.5-5 mg once daily. Elderly patient & those w/ hepatic impairment Lower initial doses may be used.
Click to view Corpulax detailed prescribing information
Overdosage
View Corpulax overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Click to view Corpulax detailed prescribing information
Special Precautions
Possible symptomatic hypotension particularly in patients w/ severe aortic stenosis. Worsening angina & acute MI can develop after starting or increasing the dose, particularly in patients w/ severe obstructive CAD. Amlodipine will not protect against the consequences of abrupt β-blocker w/drawal; gradual β-blocker dose reduction is recommended. Titrate slowly when administering to patients w/ severe hepatic impairment. Safety in pregnancy & lactation has not been established.
Click to view Corpulax detailed prescribing information
Use In Pregnancy & Lactation
Click to view Corpulax detailed prescribing information
Adverse Reactions
Edema, dizziness, flushing, & palpitation. Fatigue, nausea, abdominal pain, somnolence.
Click to view Corpulax detailed prescribing information
Drug Interactions
May produce additive antihypertensive & antianginal effects w/ SL nitroglycerin, long-acting nitrates, β-blockers or other antianginal agents. Increased systemic exposure w/ diltiazem. Plasma conc may be increased w/ strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir). Closely monitor BP when co-administered w/ CYP3A4 inducers.
Click to view Corpulax detailed prescribing information
Storage
View Corpulax storage conditions for details to ensure optimal shelf-life.
Description
View Corpulax description for details of the chemical structure and excipients (inactive components).
Action
View Corpulax mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Calcium Antagonists / Anti-Anginal Drugs
ATC Classification
C08CA01 - amlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Regulatory Classification
Rx
Presentation/Packing
Form
Corpulax tab 10 mg
Packing/Price
100's
Form
Corpulax tab 5 mg
Packing/Price
100's